ST Ming (002581.SZ) has obtained an ethical approval for the phase III clinical trial of a class of innovative drug, recombinant human nerve growth factor SMR001 eye drops.

Zhixin Finance and Economics APP News, ST Weiming (002581.SZ) announced that its wholly-owned subsidiary Shandong Yandu Bio-Technology Co., Ltd. has recently obtained approval from the Ethics Committee of Beijing Tongren Hospital, affiliated to Capital Medical University, for the Phase III key registration clinical trial of innovative drug recombined human nerve growth factor SMR001 eye drops (referred to as "SMR001 eye drops") for the treatment of moderate to severe dry eye syndrome. The project has been officially launched.